source
- Biotech sector rebounds but gains are uneven, with Chinese firms and a large Sofinnova fund leading the surgeBiotech companies are experiencing a strong year overall, yet investor reactions to positive clinical data remain mixed. Chinese biotech firms are emerging as the top performers, outpacing many pe…
- Eli Lilly makes 14th acquisition of 2026, buying a blood-cancer biotechEli Lilly announced it has acquired a blood‑cancer focused biotechnology company, marking its 14th acquisition in 2026. The deal reflects Lilly’s aggressive expansion strategy, funded by strong sa…